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The  main  obstacle  to  successful  organ  transplantation  today  is  the  recipient's 
recognition of the implanted ceils as foreign, and his reaction to this intrusion through 
cellular and/or humoral mechanisms normally triggered by infectious microorganisms 
(1).  The  tempo  and  intensity of  this  immunological response  are  conditioned sig- 
nificantly by the degree of genetic or antigenic disparity existing between donor and 
recipient  (2).  This  consideration has  stimulated an intensive search for  techniques 
capable of selecting optimally compatible donor-recipient pairs for organ transplanta- 
tion. Such techniques include in vivo tests performed with skin allografts (third man 
test) or with lymphocytes (normal lymphocyte transfer test) obtained from prospec- 
tive donors  and  recipients, and  in  vitro  cellular  (mixed lymphocyte cultures)  and 
serological (leukocyte group antigens) reactions (3). The latter effort, largely stimu- 
lated by the classical studies of Gorer and Snell and their associates (4-7), has pro- 
vided cogent evidence for  the  existence in  different mammalian species of a  major 
system of histocompatibility whose components are amenable to serological analysis 
and definition. Such histocompatibility systems include the routine 1t-2 system  (6), 
HL-A in man (8), Ag-B (9)  or RtH-1  (10)  in rats, GPL-A in guinea pigs (11), PL-A 
in pigs (12), ChL-A in chimpanzees (13),  and RhL-A in rhesus monkeys (14). 
Another important approach to  the  transplantation problem has been concerned 
with  the  search for  specific immunological techniques  capable of inducing aUograft 
tolerance without  interference with  the  remainder of  the  host's immunological de- 
fenses  (1).  Historically, this endeavor began with  the  studies of Medawar  and  his 
associates in 1951 (15),  and led to Billingham, Brent, and Medawar's (16)  definition 
of immunological tolerance as a  weakening or suppression of Mlograft responsiveness 
through exposure of the host to specific antigenic stimulation before the development 
of  immunolcgical  competence.  Since  then,  this  concept  has  been  broadened  con- 
siderably,  and  the  dividing  lines  between  classical  immunological  tolerance  and 
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serologically  mediated  allograff  enhancement  (17,  18)  have  become  increasingly 
tenuous  (15).  It has also been reported that treatment of adult animals with trans- 
plantation  antigens  after  the  development  of immunological  competence may  de- 
crease allograft reactivity in the recipients  (19-22). As noted in the classical  mono- 
graph of van Bekkum and de Vries  (23),  the combined use of total body irradiation 
and bone marrow transplantation in rodents has provided an alternative and uniquely 
important approach to this problem. 
In their attempt to extend the latter experimental approach to the canine species, 
Ferrebee  and  Thomas and  their  associates  established  a  selectively bred  colony cf 
beagles at the Mary Imogene Bassett Hospital  (24),  and observed that only an oc- 
casional dog exposed to supralethal  total body irradiation and given a bone marrow 
transplant from a randomly selected donor survived this treatment without untoward 
effects  (25).  Such survivors were also unresponsive  to skin allografts obtained front 
their donor of marrow (25).The one long-term renal allograff of Mannick et al. (26) and 
the one long-term lung allograft of Blumenstock et al.  (27) performed under similar 
experimental  conditions suggested  that  these radiation  chimeras might also  be un- 
responsive to other tissues obtained from the donor of marrow. The principal obstacle 
to more extensive study of this experimental model was the unavailability of methods 
of donor selection capable of providing a regularly reproducible take and a long-term 
survival  of a  bone marrow  transplant  in  the  dog.  Most  bone marrow  transplants 
either failed to take or caused fatal secondary graft-versus-host  (GVH) 1 disease  in the 
recipients  (28).  Some means  of prospective selection  of compatible  donor-recipient 
pairs thus appeared to be essential to permit progress of this endeavor. 
In further studies  of this  question,  Kasakura,  Thomas, and Ferrebee  (29),  Puza 
et  al.  (30),  Rubinstein  and  Ferrebee  (31),  Cleton,  van Es,  Ponsen,  and  van Rood 
(32),  Cohen and Kozari (33), and Epstein,  Storb, Ragde, and Thomas (34) observed 
that immunization of dogs, and particularly of littermatcs  (34), with buffy coat cells 
resulted in the appearance of leukocyte group-specific isoantibodies in the recipients. 
In an extension of the elegant studies of Epstein et al.  (34), Rubinstein and associates 
(35), and Mollen et al.  (36) produced a battery of typing sera capable of detecting 10 
different leukocyte antigen  specificities  (or sets of specificities)  in the  Cooperstown 
colony of beagles.  Transplantation  studies performed on the basis of donor-recipient 
compatibility for these antigens  in the  Cooperstown Cclony have shown that allo- 
grafts of skill  (36),  kidney  (37),  heart  (38),  lung  (39),  and liver  (40) are accorded 
prolonged survivals in compatible animals. Conversely, allografts transplanted across 
major leukocyte group incompatibilities are rejected  rapidly.  This  result, taken  to- 
gether with  evidence that such leukocyte antigens behave as Mendelian  autosomal 
dominants in the Cooperstown Colony (41),  suggested that these leukocyte antigens 
were components of a  single  major system of histocompatibility, for which the term 
DL-A  was  proposed  (37).  Bos et  M.  (42),  Westbroek  et  al.  (43),  Templeton  and 
Thomas (44), and Vriesendorp et al.  (45) have recently provided additional evidence 
to support the existence of this major histocompatibility locus in the canine species. 
Recent  studies  of  the  segregation  of  the  components  of the  DL-A system in  679 
offspring of 141  consecutive matings in the Cooperstown Colony have identified  23 
1 Abbre'dations  used  in  this" paper:  DIH,  distemper4nfectious  hepatitis  vaccine;  GVH, 
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different DL-A haplotypes  (i.e.,  specificities,  or  sets of  specifieifies,  determined by 
the DL-A region of one chromosome)  in this colony (46), and have demonstrated that 
all currently known DL-A antigen(s) are regularly transmitted en bloc from parents 
to  offspring,  with no evidence of independent segregation. These  studies have also 
resulted in the definition of the DL-A genotypes of 1302 offspring  of 517 matings in 
the Cooperstown Colony (46). Preliminary studies (47, 48) have raised the possibility 
that  the  application of  such  genotypic criteria  of  donor-recipient DL-A  identity 
might considerably improve the results of bone marrow transplantation in the canine 
species  (49). 
This  report  describes  the  long-term survival of  17  consecutive irradiated 
recipients  of  bone  marrow  allografts  obtained  from  prospectively  selected 
genotypically DL-A-identical donors,  11  littermate and 6  nonlittermate. The 
recipients are thus far surviving without evidence of GVH disease for periods 
of 211-649 days, and are unresponsive to kidney and skin allografts obtained 
from their donor of marrow. They have, however, rejected DL-A-incompatible 
skin allografts obtained from other donors at the same rate as untreated dogs. 
The  results  suggest  that  total  body irradiation and  transplantation of  bone 
marrow from a  genotypically DL-A-identical donor induces in the recipient a 
state of unresponsiveness to other tissue allografts from the same donor. The 
immunological specificity of this tolerant state is demonstrated by the  ability 
of the recipients to reject promptly allografts obtained from other donors. 
Materials  and  Methods 
Selection  of Donors  and  Recipients.--Adult  male and female beagles of the Cooperstown 
Colony weighing 18-25 lb. were used throughout this study. Donor-recipient pairs for bone 
marrow transplantation were selected on the basis of genotypic evidence of DL-A identity. 
The DL-A genotypes of all of the animals used were obtained as a result of the earlier definition 
of the DL-A haplot3~pes and of their segregation in each succeeding generation of the various 
different lines of selectively bred animals maintained in the colony (46). Deduction of each 
genotype was confirmed by serological testing with a standard battery of lymphocytotoxic 
DL-A antisera. The method of preparation  of these antisera and the typing technique used 
have been described previously (34-37). 12 different DL-A specificities (or sets of speeificlties) 
were detected by this method, including b, c, d, e, f, g, h, k, l, m, n, and o. Erythrocyte  group 
antigens A, C, and D were detected with the typing sera and by the technique of Swisher and 
Young (50). Coefficients of relationship of each donor and recipient and of their respective 
parents were determined  in each experiment. 
Method  of  Total  Body  Irradiation  and  Bone  Marrow  Transplantation.--The  method  of 
supralethal total body irradiation has been described in detail previously (51). Each recipient 
was exposed to  1200-1400 R  of continuous irradiation  from two opposing 6°Co sources, at 
a source-to-target distance of 2-2.5 m, with an exposure rate of 3-4 R/rain. 12-18 hr later, a 
bone marrow transplant obtained from a prospectively selected genot)'pically DL-A-identical 
donor was performed by a  modification of the  standard technique  (52), consisting of  the 
intravenous infusion of a suspension of 3-3.5 X  10  q nucleated bone marrow cells obtained by 
needle aspiration of the long bones and sternum of the donor (52). Leukocyte and platelet 
counts were performed three times weekly for the first 21 days after irradiation and at weekly 
intervals thereafter.  Return of leukocyte and platelet levels to normal values after treatment 
and the absence of GVH disease constituted evidence of successful take and proliferation of RAPAPORT  ET  AL.  1083 
the bone marrow transplant  (53). Persistence of chimerlsm was confirmed at regular intervals 
by the continuing presence of donor erythrocyte group antigens in the recipient, and by the 
appearance  of the sex characteristics  of donor cells in  tile recipient's peripheral leukocytes 
(54). 
Method of Study oJ" Serum  Antibody  Responses.--Each  animal received an intramuscular 
injection of 1 ml of distemper and infectious hepatitis (DIH) vaccine (prepared by Dr. James 
A.  Baker,  Veterinary Virus  Research Institute,  Cornell  University, Ithaca,  N.  Y.)  at  the 
age of 3 months (55). Serum antibody levels were determined immediately before irradiation. 
The  animals  received additional  booster  immunizations  of  1  ml  of  vaccine before kidney 
transplantation  and  at  various  intervals  thereafter.  Anti-distemper  and  anti-infectious 
hepatitis virus antibody determinations were performed in Dr. Baker's laboratory by stand- 
ard viral neutralization tests (56, 57). 
Methods of Grafting and Criteria for the Assessment of Allograft Survival.--Within 43-120 
days  after  bone  marrow  transplantation,  each  recipient  underwent  bilateral  nephrectomy 
under  general halothane  anesthesia,  followed immediately by  transplantation  of a  kidney 
obtained from the bone marrow donor. The technique of transplantation  has been described 
previously (37). Complete urinalysis and blood urea nitrogen determinations were performed 
daily during the 1st month after operation, and at biweekly intervals thereafter. Criteria for the 
continued survival of each kidney transplant included normal renal function tests and evidence 
of  the  ability of  the  transplanted  kidney  to  maintain  the host's  life without  weight loss, 
anorexia,  and/or  vomiting. 
The method of skin grafting has been described in an earlier report (35). Briefly, the recipi- 
ents were anesthetized and  the hair of the lateral aspects of the chest was removed. Under 
sterile precautions,  skin surfaces measuring 2  X  2 cm were excised,  leaving the intact pan- 
niculus carnosus as the graft bed. Skin specimens of the same size were excised from the donors; 
the subcutaneous  fat was  removed from each graft by sharp  dissection, and  the graft was 
approximated  to the recipient bed with interrupted  5-0 nylon sutures.  A maximum of four 
grafts  was  applied  in  duplicate  to  each  recipient.  Vaseline  gauze  and  compressive gauze 
dressings were placed on the transplants,  and then covered with an adhesive bandage.  Dress- 
ings were removed on the 7th postoperative day, and the grafts were then examined daily.  A 
graft was considered to have undergone rejection when 75% of the transplanted  tissue  had 
become hard,  opaque, or necrotic. The diagnosis of rejection was confirmed in each instance 
by sloughing of the eschar. 
For the purposes of this study, each recipient was tested with skin allografts within 230-450 
days after bone marrow transplan ration. The skin grafts were obtained from the bone marrow 
donor and from a maximum of three other donors selected on the basis  of varying degrees  of 
DL-A compatibility with the recipients. 
RESULTS 
The  DL-A  genotypes  and  coefficients  of relationship  of  the donor-recipient 
pairs presented  in this report  are outlined in Table I.  11  animals received bone 
marrow  transplants  from  DL-A-identical  littermates.  The  sires  and  clams  of 
each pair of animals in this group were completely unrelated in three instances; 
the  coefficients  of  relationship  of  the  other  eight  sets  of  parents  varied  from 
7/(6  to 1/(2 s.  Six dogs received bone  marrow  transplants  from DL-A-identical 
nonlittermate  donors.  The  donor-recipient  coefficients  of  relationship  ranged 
from ~  to s 7~ 12; the coefficients of relationship of the parents of each individual 
donor and recipient in this group ranged from 23,~4 to zero. 
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marrow  transplantation  are  summarized  in  Table  II. There  was  a  uniform 
decrease  in  leukocyte  and  platelet  levels  during  the  first  10-12  days  after 
irradiation,  with  leukocyte counts in  the  range  of 99-311/mm  ~,  and platelet 
counts in the range of 4600-63,000/mm  *. These values returned to normal levels 
within 20-110 days after bone marrow transplantation, with leukocyte counts 
ranging  from  6300  to  12,000/ram  3,  and  platelet  counts  from  107,000  to 
257,000/mm  3. The serological responses of each recipient to immunization with 
TABLE I 
DL-A  Genoty#es  and  Coefficients  of Relationship  of Bone Marrow Donors  and Recipients  and 
Their Parents 
Donor-  Coefficient of relationship 
DL-A genotype of  Donor-recipient  recipient  of parents of 
Donor  Recipient  each donor and  relation  coefficient of 
recipient  pair  relationship  Donor  Recipient 
21-53  21-54  bkhfm/gln  Littermates  1/2  23/64  23/64 
21-59  21-60  bkhfm/bkhfm  "  1/2  0  0 
21-62  21-61  bkhfm/bkhfm  "  1/2  0  0 
21-65  21-66  gln/be  "  1/2  7/16  7/16 
21-74  21-73  bkhfm/bkhfm  "  1/2  3/32  3/32 
22-21  22-22  gln/gln  "  1/2  0  0 
21-95  21-96  bkhfm/bkhfm  "  1/2  7/32  7/32 
22-32  22-29  gln/gln  "  1/2  3/16  3/16 
22-03  22-04  bkcdn/bkhfm  "  1/2  7/64  7/64 
2243  2240  bkhfra/ghl  "  1/2  37/128  37/128 
22-55  2248  bkhfm/bkhfm  "  1/2  1/128  1/128 
21-87  21-56  bkhfln/bkhfm  Nonlittermates  85/256  13/64  23/64 
21-90  21-97  bkhffn/bkhfm  "  87/512  13/64  7/32 
22-06  22-24  gln/g[n  "  i/8  25/256  0 
22-51  22-57  bkhfm/bkhfm  "  77/512  1/128  13/64 
22-52  22-56  bkhfm/bkhfm  "  77/512  1/128  13/64 
22-46  22-07  gln/gln  "  163/512  3/32  25/256 
DIH vaccine are also summarized in Table II. There was a relative decrease in 
antibody titers  to distemper  and infectious hepatitis  viruses  during  the  early 
postirradiation and transplantation period. As noted in Table II, however, such 
titers generally returned to normal levels within 3-6 months after bone marrow 
transplantation. At that time, the titers were roughly comparable to antibody 
levels  in the recipients before irradiation. 
The results of bone marrow transplantation are outlined in Table III. Bone 
marrow allografts obtained from prospectively selected DL-A-identical donors 
are currently surviving for 211-649 days without evidence of GVH disease  in 
17 consecutive recipients. These include 11 recipients of bone marrow obtained 
from littermates  (315, 364, 424, 440, 531,531,584, 605,625, 645, and 649 days, 
respectively)  and 6 recipients  of transplants  from nonlittermate  donors  (211, 
279, 280, 418, 479, and 480 days, respectively). Evidence of persisting chimerism RAPAPORT ET AL.  1085 
has  been  obtained  at  regular  intervals  in  eight  informative  donor-recipient 
pairs on the basis of changes in the recipients' erythrocyte group antigens after 
bone  marrow  transplantation  (recipients  21-60,  21-61,  21-66,  21-73,  21-96, 
22-04,  21-97,  22-56). Similar evidence has been obtained in eight pairs by the 
observation that the recipients' peripheral blood leukocytes had acquired the 
TABLE II 
Effects of Supralethal  Total Body Irradiation  and Bone Marrow Transplantation  in Sdectively 
Bred DL-A-Identical  Donor-Reciplent Pairs of Beagles 
Donor 
21-53 
21-59 
21-62 
21-65 
21-74 
21-95 
22-03 
22-32 
22-21 
22-43 
22-55 
21-87 
21-90 
22-06 
22-52 
22-51 
2246 
cipient 
21-54 
21-60 
21-61 
21-66 
21-73 
21-96 
22-04 
22-29 
22-22 
2240 
22-48 
21-56 
2107 
22-24 
22-56 
22-57 
22-07 
Relation 
Littermate 
~c  gc 
gc  c¢ 
Nonlitter- 
mate pairs 
gc  gc 
Leukocyte/platelet levels* of 
recipients at 
7-12 days 
after 
irradiation 
99/4,666 
266/17,500 
240/24,250 
177/9,600 
177/17,500 
33/48,000 
288/63,000 
133/20,500 
155/25,000 
211/19,000 
200/30,000 
300/32,000 
22-110  days after 
bone marrow 
transplantation 
10,800/241,000 
12,000/257,000 
10,300/220,000 
8,800/213,000 
12,900/160,000 
6,300/195,000 
11,600/225,000 
9,800/127,000 
10,500/107,000 
10,300/137,000 
8,000/200,000 
14,600/171,000 
Serum antibody titers in recipients 
Before irradiation 
Dis- 
temper 
> 1/101 
>1/10 
>l/lOq 
>1/101 
>1/101 
>1/10~ 
>1/10~ 
1/310~ 
1/2o~ 
1/2001 
1/200 
1/5oo 
311/36,500 12,700/190,000 1/310 
133/26,000111,200/189,00011/1800 
277/49,0001 6,500/169,00011/125 
166/37,50011,400/220,000/1/400 
144/15,400 10,000/156,000 1/310 
Infectious 
hepatitis 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
1/690 
1/3,100 
1/6,300 
1/16,o~ 
1/3,100 
3-6months after 
bone marrow 
transplantation 
Dis-  Infectious 
temper  hepatitiss 
11/180 11/1,250 
~1/125 11/16,000 
1/800  1/25 000 
1/200011/800 
1/1250/1/12,500 
1/800  1/8,000 
1/310  1/15,800 
1/31OOl/31o 
1/5ooo/1/3,1oo 
1/5000il/8,000 
1/80  1/12,500 
1/2000 1/3,100 
1/31o  11/4oo ]1/25,000 
1/3,100  1/2000/1/12,500 
1/25,00011/31011/12,5oo 
1/25,0001/100  11/25 000 
1/4,000  1/800 1/2,500 
* Per mm  3 of blood. 
sex  characteristics  of  their  corresponding  bone  marrow  donors  (recipients 
21-61,  21-96,  22-29,  22-40,  22-48,  22-56,  22-57,  22-07). 
As noted in Table IV, renal allografts obtained from the bone marrow donors 
are currently maintaining normal function in 11 littermate recipients (234, 313, 
377, 378, 441,444, 482, 557, 580, 581, and 586 days, respectively) and in 6 non- 
littermate recipients (191,  200,  221,  349,  361,  and 405  days, respectively). In 
contrast, renal allografts in 13 untreated littermate recipients under comparable 
conditions of DL-A compatibility were rejected in  13-38 days (mean survival 1086  FIISTOCOM.PATIBILITY STUDIES  IN  DOGS.  IV 
time  [MST]  =  28.3  days).  Renal  allografts  in  untreated  recipients  of DL-A- 
incompatible transplants  survived 11-20 days in eight littermates (MST  =  14.8 
days)  and  10-18  days in 19 nonlittermates  (MST  =  12.4 days). 
The  responses  to skin  allografts  observed  in the bone  marrow  chimeras  are 
outlined  in Table  V.  13  of  14  grafts  obtained  from  the  donors  of marrow  are 
surviving in  a  manner  indistinguishable  from  the behavior  of skin  autografts. 
TABLE  III 
Results of Bone Marrow Transplantation in Prospectively Selected Genotypically DL-A-Identical 
Pairs of Beagles 
Donor  Recipient  Relation 
Swisher  erythrocyte groups of  Sex markers of 
Survival 
of bone  Recipient  Recipient 
marrow  after  Do-  Recip-  after 
transplant*  Donor  Recipient  trans-  nor  lent  trans- 
plantation  plantation 
days 
21-53  21-54  Littermate  >649  AC  AC  AC  M  M  M 
pairs 
21-59  21-60  "  "  >645  C  A  C  M  M  M 
21-62  21-61  "  "  >625  AC  C  AC  F  M  F 
21-65  21-66  "  "  >605  C  AC  C  M  .V£  M 
21-74  21-73  "  "  >584  C  A  C  M  M  M 
21-95  21-96  "  "  >531  A  AC  A  M  F  M 
22-03  22-04  "  "  >531  AC  A  AC  F  F  F 
22-32  22-29  "  "  >440  C  C  C  F  M  F 
22-21  22-22  "  "  >424  C  C  C  M  M  M 
22-43  22-40  "  "  >364  AC  AC  AC  F  M  F 
22-55  22-48  "  "  >315  AC  AC  AC  F  M  F 
21-87  21-56  Nonlittermate  >480  AC  AC  AC  F  F  F 
pairs 
21-90  21-97  "  "  >479  AC  A  AC  F  F  F 
22-06  22-24  "  "  >418  C  C  C  M  M  M 
22-52  22-56  ....  >280  AC  A  AC  F  M  F 
22-51  22-57  "  "  >279  AC  AC  AC  M  F  M 
22-46  22-07  "  "  >211  AC  AC  AC  F  M  F 
* All recipients are surviving uneventfully, with no evidence of secondary disease,  as of 
15 May 1972. 
In seven of eight recipients of littermate bone marrow, the current skin allograft 
survival is  199,  178,  162,  122,  116,  116,  and  110 days,  respectively. In six non- 
littermate  recipients,  the  current  survival  is  107,  110,  110,  128,  143,  and  143 
days,  respectively.  One  allograft  (recipient  21-60)  developed  slow  progressive 
rejection  changes  which  were  complete  by  the  84th  day  after transplantation. 
Six  recipients  of  littermate  marrow  were  tested  with  skin  grafts  from  a 
DL-A-identical  sibling  of  the bone  marrow  donor.  These  grafts  were  rejected 
within 20-36 days  (MST  =  25.8 days). Five recipients of nonlittermate marrow 
were tested in similar fashion with skin grafts from a  DL-A-identical sibling of ghPA~Ogr  ET  AL.  1087 
the marrow donor.  These transplants  survived for 27-76  days (MST  =  56.2 
days). 
Nine  recipients  of  bone  marrow  obtained  from littermate  donors  and  six 
recipients of nonlittermate marrow were tested with one or more skin allografts 
obtained  from DL-A-incompatible donors.  The nine  dogs rejected  15  DL-A- 
incompatible skin grafts in 12-26 days (MST  =  16.3 days); the second group 
TABLE  IV 
Responses to Donor-Specific Kidney Allografts in DL-A-Identical Bone Marrow Chimeras 
Relation  Kidney allograft survival times (No.  of transplants per days listed) 
Experimental  between  No.  Mean 
donor  of  survival 
group  and re-  dogs  10-15 16-30 31-45  46-  lO1-  cipient  100  190  191-250 251-400  401-500  501-600  time 
Bone marrow* 
chimeras 
LM*  11 
Non-  6 
LM 
1  3  3  4 
(>  234)  (>  313)  (>  441)  (>  557) 
--  (>  377)  (>  444)  (>  580) 
(>  378)  (>  482)  (>  581) 
(>  S86) 
3  2  1 
(>  191)  (>  349)  (>  405)  -- 
--  (>  200)  (>  361) 
(>  221) 
days 
Untreated  LM  13  1  5  7  .......  28.6 
DL-A corn-  Non-  9  --  6  3  ......  28.3 
patible  LM 
Untreated  LM  8  6  2  ......  14.8 
DL-A in-  Non-  19  17  2  ........  12.4 
compatible  ' LM 
* All renal allografts are smviving  with normal function as of the last date of follow-up, 15 May 1972. 
LM =  littermates. 
of six dogs rejected 11 DL-A-incompatible skin grafts in 10.5-18 days (MST  = 
14.5 days). 
As noted in Table VI, skin  allografts performed in untreated genotypically 
DL-A-identical  pairs  of  littermates  survived  for  20-29  days  (MST  =  25.5 
days). This survival was not significantly different from that of DL-A-identical 
skin allografts in littermate bone marrow chimeras, 22-36 days (MST  =  25.8 
days)  (Table  V).  It is of interest,  however,  that  reciprocal exchange of skin 
allografts between DL-A-identical pairs of normal littermates did not regularly 
result in the same survival times in both animals. In a number of instances, the 
differences in survival of two such grafts were as great as 5 days. 
DISCUSSION 
The  results  of  this  study  indicate  that  the  use  of  combined  genetic  and 
serological criteria of DL-A compatibility in the prospective selection of DL-A- TABLE  V 
Reactivity to Skin Allografts in DL-A-Identical  Bone Marrow Chimeras Bearing Donor-Specific 
Kidney Allografts 
Bone 
marrow  Recip- 
and  lent 
kidney 
donor 
21-53  ,  21-54 
21-59  21-60 
21-62  21-61 
21-65  21-66 
21-74  21-73 
21-95  21-96 
22-03  22-04 
22-32  22-29 
22-21  22-22 
22-43  22-40 
22-55  2248 
21-87  21-56 
21-90  21-97 
22-06  22-24 
22-52  22-56 
22-51  22-57 
22-46  22-07 
I Survival time of skin allografts  (days) obtained  from 
DL-A genotype 
bktffm/gln 
bkhfm/bkhfm 
bkhfm/bkhfm 
gin/be 
bkhfm/bkhfm 
gin/gin 
bkhfm/bkhfm 
gln/gln 
bkcdn/bkhfm 
bkhfm/glrl 
bkhfm/bkhfm 
bkhfm/bkhfm 
bkhfm/bkhfm 
gln/gln 
bkhfm/bkhfm 
bkhfm/bkhfm 
gin/gin 
Relationship 
I 
Bone 
3ToO~  W 
Littermates  -- 
"  i  84 
"  i178" 
"  162 
"  116 
"  >122 
"  > !!9 
"  [>116 
"  i>ll0 
Nonlitter-mates  > 143 
"  J>143 
"  >128 
"  >110 
"  >110 
"  > 107 
I  Donors with known DL-A 
J  incompatibilities 
DL-A- 
identicall  ]  r 
•  .  In-  s,bl,ng of/  I .....  a  I  I  In-  ~  -  corrtpa- 
donor  Donor  1  tible  Donor  2  tible 
J  anti-  J  anti- 
....  i gen(s)  __  gen(s) 
20 
36 
32.5 
22.5 
22 
22 
76 
27 
34 
72 
72 
12.5  gln 
19  gln 
26  gln 
16.5  gin 
18  gl 
12  bkhfm 
12  bkcdn 
13  !  o 
20  gin 
16  gln 
13.5  (  gin 
12  Ibkhfm 
18  ]gln  I 
18  gin  ! 
10.5  ibkhfm i 
12.5 
19 
14 
13 
21 
16.5 
14 
16 
11 
16 
15 
cdn 
cdn 
cdn 
edn 
bkh!m 
cdn 
cdn 
cdn 
bkcdn 
I  cdn 
c_dn 
* >  =  allografts continue  to  survive uneventfully as  of  the last date of follow-up  (15 
May  1972). 
TABLE  VI 
Reactivily to Skin Allografls in  Untreated DL-A -Identical Littermate Pairs of Beagles 
Donor  Recipient  DL-A genotype  Skin allograft survival 
d~ys 
14-57  14-58  gln/bkhfm  26 
14-58  14-57  26 
16-68  16-69  bkcdn/gln  28 
16-69  16-68  26 
15-82  15-80  bkhfm/bkhfm  25 
15-80  15-82  20 
16-91  16-90  gln/gln  29 
16-90  16-91  25 
16-89  16-88  gln/gln  27 
16-88  16-89  22 
16-76  16-78  gln/g|n  26 
16-78  16-76  24 
16-79  16-77  be/gln  26.5 
16-77  16-79  26 
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identical  donor-recipient pairs  may regularly produce long-term survivals  of 
bone marrow chimeras. A significant array of evidence supports the contention 
that this effect is specific in nature and is not a reflection of random inbreeding 
within  the  Cooperstown Colony. The coefficients of relationship of the  bone 
marrow  donors  and  recipients  and  of  their  preceding  generation,  and  the 
establishment  of long-term  chimerism  with  equal  ease  in  littermate  and  in 
nonlittermate recipients would appear to militate against such a possibility. In 
addition,  it  may  be  pertinent  to  note  the following:  (a)  The  Cooperstown 
Colony does not constitute a randomly inbred population; rather it includes a 
number  of  selectively bred  lines  (46),  some  of  which  bear  the same  DL-A 
genotypes,  while others may be phenotypically DL-A  compatible but  geno- 
typically DL-A different (46); (b)  studies in progress at this time indicate that 
DL-A-incompatible bone  marrow  transplants  regularly fail  to  survive,  even 
when performed in littermates;  (c)  genotypically DL-A-identical  allografts  of 
other tissues  transplanted  into untreated  Cooperstown Colony recipients are 
accorded relative prolongations in survival time, but invariably undergo rejec- 
tion,  in littermates as well as in nonlittermates  (46);  (d)  DL-A-incompatible 
allografts are rejected in an even more rapid manner by both littermates and 
nonlittermates (46). The relevance of the DL-A marker system to the results 
observed  is  highlighted,  in  addition,  by  the  heterogeneity of  the  animals 
studied for other markers present on other chromosomes, such as the Swisher 
erythrocyte groups, for example. 
The  long-term  survival  of  17  consecutive  DL-A-identical  bone  marrow 
allografts presented in this  study differs significantly from earlier studies by 
Epstein et al. (49), who reported a survival rate of less than 50% at 120 days 
and less than 30% at 240 days in 17 recipients of littermate marrow allografts 
selected on the basis of serological criteria of DL-A compatibility (49). These 
results  may  reflect  the  different canine  population  and  serological  reagents 
utilized by Epstein et al. (49) and their use of phenotypic rather than genotypic 
criteria of compatibility. It must be noted, however, that the data of Epstein 
et al.  (49), as well as the incidence of GVI-I reactions observed in human re- 
cipients of HL-A-identical bone marrow transplants (58, 59), may have been a 
consequence of donor-recipient incompatibilities for H-antigens which are not 
as yet detectable by currently available techniques. In this regard, the regularly 
reproducible bone  marrow  allograft  survivals  obtained in  this  study on  the 
basis  of combined genetic and  serological criteria  of DL-A  compatibility in 
selectively bred lines  of beagles may provide an  experimental model for the 
further investigation of such H-antigens and of their role in triggering GVH 
disease. Rather than localizing such determinants on chromosomes other than 
those bearing the DL-A region, however, the results  of this study raise  the 
alternative possibility that these determinants are genetically linked, i.e., they 
occur on one major autosomal complex, for which the DL-A genotype serves 
as  an  effective marker  in  the  Cooperstown  colony. Recent  reports  (60-64) 1090  HISTOCOMPATIBILITY STUDIES  IN  DOGS.  IV 
indicate that the fate of tissue and of bone marrow allografts in man and in the 
mouse may depend upon the products of at least two and possibly more closely 
linked genetic systems. Such systems include the serologically detectable HL-A 
and H2 systems, as well as products detectable by the mixed leukocyte culture 
test (MLC), and a possible cellular immunity locus (61). 
The  observation  that  bone  marrow  transplantation  in  DL-A-compatible, 
MLC-negative  littermate  dogs  (65)  and  in  HL-A-identical,  MLC-negative 
recipients of human sibling marrow (66)  are associated with significant failure 
rates, raises the possibility that, in addition  to the two postulated DL-A loci, 
and to the MLC locus, the proposed main canine histocompatibility complex 
may include  one  or more additional  closely linked  but genetically separable 
determinants, one of which might be termed a "bone marrow transplantation" 
locus.  Cudkowicz's  (67)  recent  findings of  hybrid  resistance  genes  for  bone 
marrow  transplantation  within  the  analogous  histocompatibility  complex in 
mice would appear to support this possibility. The success rate of bone marrow 
transplants observed in the Cooperstown colony may, in this regard, have been 
related to the criteria employed for the definition of DL-A genotypic identity 
between  each  littermate  or  nonlittermate  donor-recipient  pair  selected  for 
transplantation.  Such identity was based upon evidence of the transmission of 
the  same  DL-A genetic material from the  same ancestral  source  (46)  for at 
least three or four successive generations. The resulting pairs of dogs differed 
for other genetic markers,  located on other chromosomes. It is possible, how- 
ever, that the criteria of selection of donors and recipients for this study identi- 
fied, within the Cooperstown colony, those animals sharing components of the 
major histocompatibility complex other than DL-A and/or MLC determinants. 
The unresponsiveness of the radiation chimeras to kidney and skin allografts 
obtained  from the  bone  marrow  donors  is  consonant  with  the  hypothesis  of 
Main and Prehn (68)  that bone marrow transplantation may induce a state of 
tolerance  to other  tissues  obtained from the same donor.  The immunological 
specificity of the  induced  unresponsiveness is supported by the  ability of the 
chimeras  to  reject  skin  allografts  from  both  DL-A-compatible  and  DL-A- 
incompatible donors.  The capacity of the  chimeras to muster  other  forms of 
immune responses is  attested by their  production  of normal  serum  antibody 
levels against DIH vaccine within 3  6 months after bone marrow transplanta- 
tion.  This  observation is  in  agreement with  the  recent  studies  of Ochs  et  al. 
(69),  who  have provided  extensive  evidence  of normal  cellular  and  humoral 
immunological function in long-term radiation chimeras. 
13 of 14 chimera recipients of skin allografts obtained from the bone marrow 
donors have thus far tolerated such transplants as if they were autografts. One 
recipient  (recipient 21-60)  has rejected such an allogndt  in  slow fashion, with 
complete destruction  of the  transplant  by the  84th  postoperative  day. This 
chronic  response resembles the  long-term behavior of skin  allografts recently 
described in chimeric cattle twins by Stone et al. (70). The fate of the remaining RAPAPORT  ET  AL.  1091 
marrow donor-specific skin allografts is consistent, however, with the thesis that 
the  chimeras  are  generally  rendered  tolerant  to  skin  as  well  as  to  kidney 
allografts  from the  bone marrow  donors.  This  conclusion evidently requires 
confirmation by a longer period of follow-up of these skin grafts. In this regard, 
it may be pertinent to note that opinions concerning the ability of bone marrow 
transplants  to induce tolerance to skin  are  somewhat divided.  Some authors 
suggest that bone marrow transplantation only induces an incomplete or split 
form of tolerance to  other tissues  (71-73),  and Lance  (74)  has  recently de- 
scribed skin-specific differentiation alloantigens  in  mice.  On  the  other  hand, 
Main and Prehn (68) and Thomas and Ferrebee (25) have described long-term 
survivals of skin allografts in radiation chimeras,  and Wood  et al.  (75)  have 
recently observed tolerance to skin allografts in mice treated with  antilympho- 
cyte serum and bone marrow cells. 
The rejection of skin allografts obtained from other DL-A-identical  donors 
further supports  the individual-specific nature  of the  state of allograft  unre- 
sponsiveness  induced in  the  recipients.  It  also  highlights  the  immunological 
consequences  of host  reactivity to  non-DL-A  or  "weak"  histocompatibility 
antigens (76-78) present in the skin graft donors but absent  in the recipients. 
This result,  taken together with  the  differences in survival  of skin  allografts 
exchanged reciprocally between untreated pairs of DL-A-identical  littermates 
(Table VI), supports the conclusion of Graft et al.  (79)  that, in the  absence of 
strong donor-recipient incompatibilities, otherwise weak immunogens may exert 
a  cumulative effect upon allograft survival. The results also suggest that  the 
bone marrow donors and recipients reported in this study, while genotypically 
DL-A identical, :nay differ by a  varying,  albeit probably limited number of 
other  H  determinants.  The long-term  survival  of  bone  marrow  transplants 
in the absence of GVH disease in such recipients suggests that relative degrees 
of  accommodation  to  such  non-DL-A  histocompatibility barriers  mav  have 
been  developed  by  the  immunologically  competent  cells  transplanted  into 
irradiated recipients. This possibility may provide an explanation for the partial 
unresponsiveness  accorded by radiation  chimeras  to skin  allografts obtained 
from DL-A-identical littermate siblings of the marrow donors, when such allo- 
grafts  were  applied  to  recipients  of bone  marrow  cells  obtained  from  non- 
littermate DL-A-identical donors. As noted in Table V,  these grafts survived 
for 27-72 days (MST -= 56.2 days), while similar grafts performed in recipients 
of littermate bone marrow transplants were rejected within 20-36 days (MST = 
25.8  days).  Such  a  difference  in  survival  raises  the  possibility  that  the 
individual-specific nature of the unresponsiveness to skin allografts produced 
in  radiation  chimeras  may  have  been  broadened  in  nonlittermate  marrow 
recipients to a partial tolerance to skin allografts obtained from DL-A-identical 
silbings of the bone marrow donors. Such an effect may have been due to the 
possibility that the bone marrow cells transplanted into nonlittermate recipients 
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was the case in littermate marrow transplants. This possibility is supported by 
the relationships reported between the strength of histocompatibility barriers 
and  the induction of immunological tolerance in mice  (80),  and is consistent 
with the recent observations of Hussey et al. (81)  of the occasional success of 
bone marrow and renal allografts in mongrel dog radiation chimeras. 
The precise nature  of the  mechanisms  implicated in  the  type  of allograft 
unresponsiveness described in this stucD  ~  is not clear at present. It is of interest, 
however,  that  blocking  antibodies  of the  Hellstrtim type  (82)  have recently 
been described in long-term canine bone marrow chimeras (83), and that such 
antibodies  have  also  been  reported  in  long-term  recipients  of  human  renal 
allografts (84). These observations may be of direct relevance to further studies 
of mechanisms of allogeneic unresponsiveness in radiation chimeras. 
SU1VIMARY 
17  Cooperstown  beagles  of  known  DL-A  genotypes  were  exposed  to 
supralethal total body irradiation and received a bone marrow allograft from a 
DL-A-identical donor; 11 littermate and 6 nonlittermate donor-recipient pairs 
were studied. The recipients are surviving uneventfully for 315,364, 424, 440, 
531,531,584, 605,625, 635, and 649 days in the littermate group and for 211, 
279,  280, 368, 479, and 480 days in the nonlittermate group. 
The  radiation  chimeras  underwent  bilateral  nephrectomy and  received  a 
kidney allograft obtained from their respective marrow  donor within  43-120 
days after bone marrow transplantation. The renal allografts are surviving for 
191,  200,  221,  234,  313,  349,  361,  377,  378,  405, 441,  444, 482, 557, 580,  581, 
and 586 days, respectively. 
12 of 13 skin allografts obtained from the marrow donor are at present sur- 
viving in the recipients for 107,110, 110, 110, 116, 122, 128, 143, 143, 162,  178, 
and 199 (lays, respectively; one graft was rejected at 84 days. In contrast, the 
radiation chimeras rejected 25 skin allografts obtained from DL-A-incompatible 
donors within  10.5-21  days  (MST  =  15.2  days).  Skin  transplants  obtained 
Dora DL-A-identical siblings of the bone marrow donors were rejected within 
20-36  days  (MST  --  25.8 days)  in  recipients of bone marrow cells obtained 
from littermate donors. Recipients of nonlittermate bone marrow transplants 
accorded such allografts a prolonged survival time of 27-76 days (MST =  56.2 
days). 
Prospective selection of genotypically DL-A-identical donor-recipient pairs 
results in  the  regularly reproducible long-term survival of bone marrow  allo- 
grafts.  The  radiation  chimeras  produced  in  this  manner  have  developed  a 
donor-specific state of unresponsiveness to kidney and skin allografts. The re- 
sults  are  consistent with the existence in  the  canine species of at least three 
closely  linked  genetic  systems  relevant  to  transplantation,  including  DL-A, 
MLC, and a possible bone marrow transplantation locus. 
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